. Author manuscript; available in PMC: 2018 Jun 23.

Published in final edited form as: J Med Chem. 2017 Jul 13;60(14):6364–6383. doi: 10.1021/acs.jmedchem.7b00561

Table 5.

Synergistic Activity of 7a and 7ii with Selected HCV Therapeutics

entry	program	parameter	ribavirin	sofosbuvir	telaprevir	daclatasvir	cyclosporin A	boceprevir
7a	CalcuSyn	CI value^a	0.770 ± 0.189	1.13 ± 0.12	0.775 ± 0.108	0.510 ± 0.082	0.625 ± 0.136	ND
		synergy volume^b	++	±	++	+++	+++	ND
	MacSynergy	synergy volume^c	+++	+	+++	+	++	ND
7ii	CalcuSyn	CI value^a	0.745 ± 0.084	0.759 ± 0.076	0.740 ± 0.102	0.831 ± 0.133	0.867 ± 0.115	0.782 ± 0.104
		synergy volume^b	++	++	++	+	+	++
	MacSynergy	synergy volume^c	++	+++	+++	+++	++	++

Values are mean ± SEM of combination indices (CI) obtained from combinations of the tested drug with 7a or 7ii at or near their EC₅₀ values when tested alone (n ≥ 6).

The level of synergy is defined as the following: ± means nearly additive (0.9 ≤ CI < 1.1), + means minor synergy (0.8 ≤ CI < 0.9), ++ means moderate synergy (0.7 ≤ CI < 0.8), and +++ means strong synergy (CI < 0.7).

The levels of synergy are defined as the following: ± means nearly additive (0 ≤ log volume <2), + means minor synergy (2 ≤ log volume <5), ++ means moderate synergy (5 ≤ log volume <9), and +++ means strong synergy (log volume >9).